Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

89Zr F8scFv

Next Previous
Search
Drug Profile

89Zr F8scFv

Alternative Names: 89Zr-DFO-N-Suc-F8scFv; Zirconium-89 Labelled Vartumab

Latest Information Update: 07 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VAR2 Pharmaceuticals
  • Class Antineoplastics; Diagnostic agents; Drug conjugates; Imaging agents; Monoclonal antibody diagnostics; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 06 Nov 2024 89Zr F8scFv is available for licensing as of 17 Oct 2024. https://var2pharma.com/about/collaborations/
  • 17 Oct 2024 Var2 Pharmaceuticals plans the phase 0 VARTUTRACE trial for Solid Tumors (Diagnosis) (IV) in Netherlands, in November 2024 (NCT06645808) (EudraCT2024-513827-18-00)
  • 30 Sep 2024 Preclinical trials in Solid tumours in Denmark (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top